HSE Considering Public Reimbursement for Mounjaro and Other Weight-Loss Drugs
“The medications are licensed for a body mass index greater than 30 or greater than 27 with a weight-related complication,” Dr Michael Crotty said as Ireland’s health service weighs multiple applications for state-funded anti-obesity treatments.
The Health Service Executive is actively considering applications to cover several weight-loss drugs known as GLP-1 medications through its drug reimbursement process. The HSE Drugs Group met to evaluate the drug Mounjaro, known generically as Tirzepatide and manufactured by Ely Lily, though no formal recommendation has yet been delivered to the HSE Senior Leadership Team.
Key Clinical Takeaways:
- The HSE is reviewing reimbursement applications for multiple GLP-1 weight-loss medications, including Mounjaro and Wegovy.
- Ely Lily submitted a pricing offer for Mounjaro that would cost the Irish state approximately €2 billion to €3 billion annually.
- Current public access is restricted primarily to approximately 45,000 patients on the Long-Term Illness Scheme and 8,000 medical card holders prescribed Ozempic strictly for Type 2 diabetes.
Financial Impact of Ely Lily Pricing Offer on State Budget
The evaluation of Tirzepatide centers heavily on its projected financial burden. Ely Lily submitted a new pricing offer in recent months that would cost the State between €2 billion and €3 billion each year if the treatment were integrated into the public healthcare system. The HSE noted that negotiations with manufacturers can take some time and there may be a number of meetings of the Drugs Group before any definitive recommendation reaches senior management.
Complementing these deliberations, a cost-benefit assessment for another weight loss drug, Wegovy, is due soon. These financial evaluations intersect with broader health policy discussions involving the Department of Health to determine how sustained expenditures will impact the wider health budget over the coming months.
A HSE expert group will meet next Tuesday to consider whether members of the public who need the weight loss drug Tirzepatide, more widely known as Mounjaro, should be able to receive it free or at a reduced cost, based on its clinical benefits https://t.co/scAXLoFcO7
HSE Evaluates Widening Access to GLP-1 Therapies
Public access to GLP-1 therapies currently remains limited. Approximately 45,000 individuals receive Ozempic free of charge under the Long-Term Illness Scheme, alongside 8,000 medical card holders, but eligibility is restricted exclusively to patients being treated for Type 2 diabetes. The HSE is evaluating whether to widen these criteria.
Irish College of GPs Clinical Lead for Obesity Dr Michael Crotty addressed the massive scope of potential claimants during an interview on Newstalk Breakfast. Dr Crotty noted that licensing parameters—covering a body mass index greater than 30, or greater than 27 with weight-related complications—would create a vast pool of eligible patients. Pointing to international precedents, Dr Crotty explained that other nations have adopted a phased approach by prioritizing individuals suffering from severe obesity and established medical complications rather than implementing universal reimbursement. He also highlighted the emergence of pre-obesity classifications, where patients exhibit excess weight without tissue or organ dysfunction, warning that early intervention strategies must be carefully balanced against finite exchequer resources.
Existing Public Provision and Future Regulatory Outlook
While newer therapies await reimbursement decisions, one treatment for weight loss, Saxenda, is already available via the HSE for specific eligible patients who satisfy weight and health criteria. Meanwhile, the pathway for expanding public access to newer therapies remains subject to ongoing health policy reviews and multi-agency discussions.
Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.